Datapoint: AstraZeneca’s Saphnelo Cleared to Treat Lupus

The FDA on Monday approved AstraZeneca’s Saphnelo for the treatment of moderate to severe systemic lupus erythematosus (SLE), the most common form of the disease. The type I interferon receptor antagonist is the first approval for SLE since 2011, when GlaxoSmithKline’s Benlysta entered the market. While Saphnelo could pose a threat, Benlysta is highly advantaged in the SLE market basket. Its intravenous form holds covered or better status for 94% of all insured lives under the medical benefit vs. 65% of lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 8/2/21

0

0

0 Comments

0

0

• Datapoint